Michael R. Cooper | Researchain

Archive Network Publication Hotspot Collaboration

Network

Latest external collaboration on country level. Dive into details by clicking on the dots.

Explore More

Hotspot

Dive into the research topics where Michael R. Cooper is active.

Explore More

Publication

Featured researches published by Michael R. Cooper.

Blood | 2006

Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics

Daniel J. DeAngelo; Richard Stone; Mark L. Heaney; Stephen D. Nimer; Ronald Paquette; Rebecca B. Klisovic; Michael A. Caligiuri; Michael R. Cooper; Jean Michel Lecerf; Michael D. Karol; Shihong Sheng; Nicholas H. G. Holford; Peter T. Curtin; Brian J. Druker; Michael C. Heinrich

Blood | 2004

Phase II Evaluation of the Tyrosine Kinase Inhibitor MLN518 in Patients with Acute Myeloid Leukemia (AML) Bearing a FLT3 Internal Tandem Duplication (ITD) Mutation.

Daniel J. De Angelo; Richard Stone; Mark L. Heaney; Stephen D. Nimer; Ronald Paquette; Rebecca Bruner-Klisovic; Michael A. Caligiuri; Michael R. Cooper; Jean-Michel Lecerf; Ganesh Iyer; Michael C. Heinrich; Brian J. Druker

Blood | 2006

Phase 1/2 Study of Tandutinib (MLN518) Plus Standard Induction Chemotherapy in Newly Diagnosed Acute Myelogenous Leukemia (AML).

Daniel J. DeAngelo; Philip C. Amrein; Tibor Kovacsovics; Rebecca B. Klisovic; Bayard L. Powell; Michael R. Cooper; Iain J. Webb; Richard Stone

Blood | 2015

BET Inhibitor CPI-0610 Is Well Tolerated and Induces Responses in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma: Preliminary Analysis of an Ongoing Phase 1 Study

Jeremy S. Abramson; Kristie A. Blum; Ian W. Flinn; Martin Gutierrez; Andre Goy; Michael B. Maris; Michael R. Cooper; Michael O'Meara; Darrell R. Borger; Jennifer A. Mertz; Robert J. Sims; Supko Jeffrey; Anas Younes

Blood | 2015

Effect of the BET Inhibitor, Cpi-0610, Alone and in Combination with Lenalidomide in Multiple Myeloma

Ka Tat Siu; Homare Eda; Loredana Santo; Miroslav Koulnis; Jennifer A. Mertz; Robert J. Sims; Michael R. Cooper; Noopur Raje

Blood | 2016

Concomitant Suppression of IKZF1, IRF4 and MYC Contribute to the Anti-Tumor Activity of the BET Inhibitor, Cpi-0610, in Disease Models of Multiple Myeloma

Ka Tat Siu; Andrew Yee; Homare Eda; Loredana Santo; Elizabeth O'Donnell; Cristina Panaroni; Jennifer A. Mertz; Robert J. Sims; Michael R. Cooper; Noopur Raje

Cancer Research | 2018

Abstract 3674: Pharmacodynamic assessment in whole blood for the BET bromodomain inhibitor CPI-0610 of target engagement in patients with progressive lymphoma

Jennifer A. Mertz; Kristie A. Blum; Anas Younes; Jeremy S. Abramson; Michael B. Maris; Ian W. Flinn; Andre Goy; Darrell R. Borger; Michael R. Cooper; Robert J. Sims

Archive | 2013

pharmacodynamics myelodysplastic syndrome: safety, pharmacokinetics, and antagonist, in patients with acute myelogenous leukemia or high-risk Phase 1 clinical results with tandutinib (MLN518), a novel FLT3

Shihong Sheng; Nicholas H. G. Holford; Peter T. Curtin; Brian J. Druker; Michael C. Heinrich; Rebecca B. Klisovic; Michael A. Caligiuri; Michael R. Cooper; Jean-Michel Lecerf; Michael Karol; Daniel J. DeAngelo; Richard M. Stone; Mark L. Heaney; Stephen D. Nimer; Ronald Paquette

Blood | 2012

Development of BET Protein Bromodomain Inhibition for the Treatment of Hematologic Malignancies

Robert J. Sims; Emmanuel Normant; Peter Sandy; Jennifer A. Mertz; Barbara J. Bryant; Michael O'Meara; Marie Green; Michael R. Cooper; Jim Audia

Archive | 2006

Short title: FLT3 antagonist tandutinib in AML or high-risk MDS

Daniel J. De Angelo; Richard M. Stone; Mark L. Heaney; Stephen D. Nimer; Rebecca B. Klisovic; Michael A. Caligiuri; Michael R. Cooper; Jean-Michel Lecerf; Michael Karol; Shihong Sheng; Nicholas H. G. Holford; Peter T. Curtin; Brian J. Druker; Michael C. Heinrich

Explore More